Cancer-specific TERT promoter mutations, which are associated with enhanced TERT mRNA expression [39–44], are seen in ~ 19% of cancers [42], with higher prevalence in melanoma, bladder, glioblastoma, urothelial, thyroid and hepatocellular carcinoma. This evidence concerns the gene TERT and thyroid gland disorder.